Back to Search
Start Over
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study
- Source :
- Journal of the National Cancer Institute. 99(3)
- Publication Year :
- 2007
-
Abstract
- Myocardial infarction is a major cause of excess long-term mortality in survivors of Hodgkin disease, but limited information exists on the effects of specific chemotherapy regimens used to treat these patients on their risk of death from myocardial infarction.We followed a cohort of 7033 Hodgkin disease patients who were treated in Britain from November 1, 1967, through September 30, 2000, and compared their risk of myocardial infarction mortality with that in the general population of England and Wales. All statistical tests were two-sided.A total of 166 deaths from myocardial infarction occurred in the cohort, statistically significantly more than expected (standardized mortality ratio [SMR] = 2.5, 95% confidence interval [CI] = 2.1 to 2.9), with an absolute excess risk of 125.8 per 100,000 person-years. Standardized mortality ratios decreased sharply with older age at first treatment, but absolute excess risks of death from myocardial infarction increased with older age up to age 65 years at first treatment. The statistically significantly increased risk of myocardial infarction mortality persisted through to 25 years after first treatment. Risks were increased statistically significantly and independently for patients who had been treated with supradiaphragmatic radiotherapy, anthracyclines, or vincristine. Risk was particularly high for patients treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (SMR = 9.5, 95% CI = 3.5 to 20.6). Risk at 20 or more years after first treatment was particularly great for patients who had received supradiaphragmatic radiotherapy and vincristine without anthracyclines (SMR = 14.8, 95% CI = 4.8 to 34.5).The risk of death from myocardial infarction after treatment for Hodgkin disease remains high for at least 25 years. The increased risks are related to supradiaphragmatic radiotherapy but may also be related to anthracycline and vincristine treatment.
- Subjects :
- Adult
Male
Cancer Research
medicine.medical_specialty
Time Factors
Myocardial Infarction
Risk Assessment
Coronary artery disease
Cohort Studies
Risk Factors
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Anthracyclines
Myocardial infarction
Registries
Risk factor
Radiation Injuries
Aged
business.industry
Absolute risk reduction
Age Factors
Heart
Middle Aged
medicine.disease
Hodgkin Disease
United Kingdom
Surgery
Regimen
Standardized mortality ratio
Oncology
Chemotherapy, Adjuvant
Research Design
Vincristine
Cohort
Female
Radiotherapy, Adjuvant
business
Cohort study
Follow-Up Studies
Subjects
Details
- ISSN :
- 14602105
- Volume :
- 99
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of the National Cancer Institute
- Accession number :
- edsair.doi.dedup.....20a446f8b6e3f52b5369f1eac072e937